Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Top notch Feasting: A Manual for Worldwide Acclaimed Eateries - 2Why is Jerome Powell being investigated? Making sense of the DOJ's probe into the Federal Reserve chair.
- 3What will happen if Artemis 2 astronauts get hit by a solar storm during NASA's ambitious moon mission?
- 4Figure out How to Store Your Gold Ventures: A Thorough Aide safely
- 5Lucky airplane passengers capture NASA's Artemis 2 moon launch from the sky
- Indian rocket launches record-breaking BlueBird 6 smartphone satellite to orbit (video)
- 75% of Arab Israelis support Arab party joining government coalition post-war, survey reveals
- What's the Fate of 5G Innovation?
- I decided to become a single mother by choice. I wasn't ready to stop dating.
- Savvy Watches: Which One Is Appropriate for You?
- 35 million tons of food go to waste yearly in the US. Experts share tips to help stop it
- First Alert: Light snow through this evening
- Ageless Tastefulness: An Outline of Valuable Gemstones and Adornments
- Europe picks companies to help build Argonaut moon lander
